Multicentre validation of a prognostic index for overall survival in chronic lymphocytic leukaemia

Hematological Oncology

Volumn 29, Issue 2, 2011, Pages 91-99

  Bulian, Pietro ^a   Tarnani, Michela ^b   Rossi, Davide ^c   Forconi, Francesco ^d   Del Poeta, Giovanni ^e   Bertoni, Francesco ^f   Zucca, Emanuele ^f   Montillo, Marco ^g   Pozzato, Gabriele ^h   Deaglio, Silvia ⁱ   D'Arena, Giovanni ^j   Efremov, Dimitar ^k   Marasca, Roberto ^l   Lauria, Francesco ^d   Gattei, Valter ^a   Gaidano, Gianluca ^c   Laurenti, Luca ^b  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

^c UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^d UNIVERSITY OF SIENA   (Italy)

^e UNIVERSITY OF ROME TOR VERGATA   (Italy)

^f ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

^g OSPEDALE NIGUARDA CA GRANDA   (Italy)

^h Maggiore Hospital   (Italy)

ⁱ UNIVERSITY OF TURIN   (Italy)

^j CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^k ICGEB Outstation Monterotondo   (Italy)

^l UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

more..

Author keywords

Chronic lymphocytic leukaemia; Nomogram; Prognosis

Indexed keywords

BETA 2 MICROGLOBULIN;

ADULT; ARTICLE; CANCER REGISTRY; CHRONIC DISEASE; CONTROLLED STUDY; FOLLOW UP; HUMAN; LYMPH NODE; LYMPHATIC LEUKEMIA; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NOMOGRAM; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NOMOGRAMS; OUTCOME ASSESSMENT (HEALTH CARE); PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 79959214932     PISSN: 02780232     EISSN: 10991069     Source Type: Journal    
DOI: 10.1002/hon.959     Document Type: Article

References (30)

1. Hamblin TJ. Prognostic markers in chronic lymphocytic leukaemia. Best Pract Res Clin Haematol 2007; 20(3): 455-468.
2. Hallek M, Wanders L, Ostwald M, et al. Serum beta(2)-microglobulin and serum thymidine kinase are independent predictors of progression-free survival in chronic lymphocytic leukemia and immunocytoma. Leuk Lymphoma 1996; 22(5-6): 439-447.
3. Hallek M, Langenmayer I, Nerl C, et al. Elevated serum thymidine kinase levels identify a subgroup at high risk of disease progression in early, nonsmoldering chronic lymphocytic leukemia. Blood 1999; 93(5): 1732-1737.
4. Reinisch W, Willheim M, Hilgarth M, et al. Soluble CD23 reliably reflects disease activity in B-cell chronic lymphocytic leukemia. J Clin Oncol 1994; 12(10): 2146-2152.
5. Sarfati M, Chevret S, Chastang C, et al. Prognostic importance of serum soluble CD23 level in chronic lymphocytic leukemia. Blood 1996; 88(11): 4259-4264.
6. Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999; 94(6): 1840-1847.
7. Ibrahim S, Keating M, Do KA, et al. CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia. Blood 2001; 98(1): 181-186.
8. Crespo M, Bosch F, Villamor N, et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 2003; 348(18): 1764-1775.
9. Rassenti LZ, Huynh L, Toy TL, et al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med 2004; 351(9): 893-901.
10. Orchard JA, Ibbotson RE, Davis Z, et al. ZAP-70 expression and prognosis in chronic lymphocytic leukaemia. Lancet 2004; 363(9403): 105-111.
11. Gattei V, Bulian P, Del Principe MI, et al. Relevance of CD49d protein expression as overall survival and progressive disease prognosticator in chronic lymphocytic leukemia. Blood 2008; 111(2): 865-873.
12. Shanafelt TD, Geyer SM, Bone ND, et al. CD49d expression is an independent predictor of overall survival in patients with chronic lymphocytic leukaemia: a prognostic parameter with therapeutic potential. Br J Haematol 2008; 140(5): 537-546.
13. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999; 94(6): 1848-1854.
14. Dohner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000; 343(26): 1910-1916.
15. Roos G, Krober A, Grabowski P, et al. Short telomeres are associated with genetic complexity, high-risk genomic aberrations, and short survival in chronic lymphocytic leukemia. Blood 2008; 111(4): 2246-2252.
16. Rossi D, Lobetti Bodoni C, Genuardi E, et al. Telomere length is an independent predictor of survival, treatment requirement and Richter's syndrome transformation in chronic lymphocytic leukemia. Leukemia 2009; 23(6): 1062-1072.
17. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008; 111(12): 5446-5456.
18. Binet JL, Caligaris-Cappio F, Catovsky D, et al. Perspectives on the use of new diagnostic tools in the treatment of chronic lymphocytic leukemia. Blood 2006; 107(3): 859-861.
19. Wierda WG, O'Brien S, Wang X, et al. Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia. Blood 2007; 109(11): 4679-4685.
20. Shanafelt TD, Jenkins G, Call TG, et al. Validation of a new prognostic index for patients with chronic lymphocytic leukemia. Cancer 2009; 115(2): 363-372.
21. Harrell FE. Regression Modeling Strategies. Springer: New York, 2001.
22. Apelgren P, Hasselblom S, Werlenius O, Nilsson-Ehle H, Andersson PO. Western Sweden Lymphoma Group. Evaluation of clinical staging in chronic lymphocytic leukemia- population-based study. Leuk Lymphoma 2006; 47(12): 2505-2516.
23. Altman DG, Royston P. What do we mean by validating a prognostic model? Stat Med 2000; 19(4): 453-473.
24. Shanafelt TD, Kay NE, Call TG, et al. MBL or CLL: which classification best categorizes the clinical course of patients with an absolute lymphocyte count >or=5×10(9) L(-1) but a B-cell lymphocyte count <5×10(9) L(-1)? Leuk Res 2008; 32(9): 1458-1461.
25. Binet JL, Auquier A, Dighiero G, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981; 48(1): 198-206.
26. Gentile M, Cutrona G, Neri A, Molica S, Ferrarini M, Morabito F. Predictive value of beta2-microglobulin (beta2-m) levels in chronic lymphocytic leukemia since Binet A stages. Haematologica 2009; 94(6): 887-888.
27. Eichhorst BF, Busch R, Stilgenbauer S, et al. First line therapy with fludarabine compared to chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia. Blood 2009; 114(16): 3382-3391.
28. Wierda WG, O'Brien S, Wang X, et al. Characteristics associated with important clinical end points in patients with chronic lymphocytic leukemia at initial treatment. J Clin Oncol 2009; 27(10): 1637-1643.
29. Brenner H, Gondos A, Pulte D. Trends in long-term survival of patients with chronic lymphocytic leukemia from the 1980s to the early 21st century. Blood 2008; 111(10): 4916-4921.
30. Rossi D, Sozzi E, Puma A, et al. The prognosis of clinical monoclonal B cell lymphocytosis differs from prognosis of Rai 0 chronic lymphocytic leukaemia and is recapitulated by biological risk factors. Br J Haematol 2009; 146(1): 64-75.